Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Zhang, Qianga; 1 | Descamps, Oliviera; 1 | Hart, Matthew J.a; 3 | Poksay, Karen S.a | Spilman, Patriciaa | Kane, Darci J.a | Gorostiza, Oliviaa | John, Varghesea | Bredesen, Dale E.a; b; 2; *
Affiliations: [a] Buck Institute for Research on Aging, Novato, CA, USA | [b] Department of Neurology, University of California, San Francisco, CA, USA
Correspondence: [*] Correspondence to: Dale E. Bredesen, Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA. Tel.: +1 415 209 2084; Fax: +1 415 209 2230; E-mail: dbredesen@buckinstitute.org.
Note: [1] These authors contributed equally to this manuscript.
Note: [2] These authors share senior authorship.
Note: [3] Current address: Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Abstract: An unbiased screen for compounds that block amyloid-β protein precursor (AβPP) caspase cleavage identified ADDN-1351, which reduced AβPP-C31 by 90%. Target identification studies showed that ADDN-1351 is a TrkA inhibitor, and, in complementary studies, TrkA overexpression increased AβPP-C31 and cell death. TrkA was shown to interact with AβPP and suppress AβPP-mediated transcriptional activation. Moreover, treatment of PDAPP transgenic mice with the known TrkA inhibitor GW441756 increased sAβPPα and the sAβPPα to Aβ ratio. These results suggest TrkA inhibition—rather than NGF activation—as a novel therapeutic approach, and raise the possibility that such an approach may counteract the hyperactive signaling resulting from the accumulation of active NGF-TrkA complexes due to reduced retrograde transport. The results also suggest that one component of an optimal therapy for Alzheimer's disease may be a TrkA inhibitor.
Keywords: AβPPneo, Alzheimer's disease, amyloid-β protein precursor, GW441756, nerve growth factor, transcriptional activation, TrkA receptor
DOI: 10.3233/JAD-130017
Journal: Journal of Alzheimer's Disease, vol. 40, no. 3, pp. 605-617, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl